Early Detection Research Network

Liver

Since 90% of patients with hepatocellular carcinoma (HCC) have underlying cirrhosis, patients with cirrhosis are candidates for HCC surveillance. Despite advances in medical technology, the 5-year survival of patients with HCC has improved minimally from 2% to 5% from 1981 to 1998. This may be largely due to diagnosis at late stage disease. These studies aim to compare the performance characteristics of the biomarkers AFP, DCP (des-gamma carboxyprothrombin) and AFP-L3 (lectin-bound AFP) in the early diagnosis of HCC.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/36/56
Under Review
Three
0d7d19387da14bd5a6c51a83cd03f27e
AFP has been approved by the FDA as a component of lab test to diagnose the risk of developing liver cancer in patients with chronic liver disease (CLD). The test measures levels of both AFP-L3 and AFP in the blood, and calculates AFP-L3 levels as a percentage of total AFP. Higher levels of AFP-L3 are associated with higher risk of developing liver cancer. According to the FDA, if the percentage of AFP-L3 is greater or equal to 10%, the risk is seven-fold that the patient will develop liver cancer in the next 21 months.
08e35912168c4410a522ae87eba5e5be
no
yes
Contents

There are currently no items in this folder.